人才建設

您所在的位置: 首頁 - 人才建設 - 師資隊伍 - 準聘長聘教師 - 教授 - 腫瘤醫院

腫瘤醫院

個人簡介

王潔,1965年生,中國醫科院腫瘤醫院內科主任,主任醫師,北京協和醫學院長聘教授。中國臨床腫瘤學會副理事長,中國醫師協會腫瘤多學科專委會主任委員。近30年來致力于肺癌分子分型基礎上精準診治及轉化研究工作。主持國自然基金重點項目、科技部專項等20余項。國家自然科學基金委杰出青年基金獲得者,以第一完成人獲得國家科技進步二等獎,獲全國創新爭先獎、何梁何利基金科學技術與進步獎、吳階平醫藥創新獎、中國青年女科學家獎、教育部創新團隊帶頭人等。


主要研究方向

肺癌、胸膜間皮瘤、胸腺腫瘤的精準診治;肺癌分子分型、免疫分型的轉化和臨床研究。


代表性成果

爆草黑丝美女|韩国19禁无遮挡啪啪无码网站|91精品国产自产精品男人的天堂|sm鞭打高潮喷水抽搐调教玩弄|果冻在线|日本大尺度吃奶呻吟视频|久久久久黄片|北条麻妃av免费观看|中文字幕一区二区人妻|亚洲最大天堂无码精品区,日韩 欧美 国产精品,国产肉丝袜在线观看,最爽无遮挡行房视频,成人H视频在线观看,糖心vlog冉冉,蜜桃产品一二三产区

1. Jie Wang#, Caicun Zhou, Wenxiu Yao, Qiming Wang, Xuhong Min, Gongyan Chen, Xingxiang Xu, Xingya Li, Fei Xu, Yong Fang, Runxiang Yang, Guohua Yu, Youling Gong, Jun Zhao, Yun Fan, Quan Liu, Lejie Cao, Yu Yao, Yunpeng Liu, Xiaoling Li, Jingxun Wu, Zhiyong He, Kaihua Lu, Liyan Jiang, Chengping Hu, Wenhua Zhao, Ben Zhang, Wei Shi, Xiaojing Zhang, Ying Cheng. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022 Jun;23(6): 739-747. (IF=54.4)

2. Jiachen Xu, Zheng Liu, Hua Bai, Guilan Dong, Jia Zhong, Rui Wan, Aiming Zang, Xiaoling Li, Qingshan Li, Jun Guo, Nan Du, Diansheng Zhong, Yan Huang, Qun Lv, Jinghua Zhang, Yue Zhao, Liming Gao, Lin Li, Chunyi Zhang, Jun Zhao, Baolan Li, Zhe Liu, Zhenlin Yang, Dong Ji, Tao Wang, Jianchun Duan, Zhijie Wang, Jie Wang*. Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2022 Jul 21. (IF=33.0)

3. Jie Wang*, Shun Lu, Xinmin Yu, Yanping Hu, Yuping Sun, Zhijie Wang, Jun Zhao, Yan Yu, Chunhong Hu, Kunyu Yang, Guosheng Feng, Kejing Ying, Wu Zhuang, Jianying Zhou, Jingxun Wu, Shiang Jiin Leaw, Jing Zhang, Xiao Lin, Liang Liang, Nong Yang. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 May 1;7(5): 709-717. (IF=33.0, ESI)

4. Jianchun Duan, Longgang Cui, Xiaochen Zhao, Hua Bai, Shangli Cai, Guoqiang Wang, Zhengyi Zhao, Jing Zhao, Shiqing Chen, Jia Song, Chuang Qi,  Qing Wang, Mengli Huang, Yuzi Zhang, Depei Huang, Yuezong Bai, Feng Sun, J Jack Lee, Zhijie Wang, Jie Wang*. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2020;6:375-84. (IF 31.7)

5. Jiefei Han, Jianchun Duan, Hua Bai, Yuqi Wang, Rui Wan, Xin Wang, Si Chen,Yanhua Tian, Di Wang, Kailun Fei, Zhuoran Yao, Shuhang Wang, Zhimin Lu, ZhijieWang, Jie Wang*, TCR Repertoire Diversity of Peripheral PD-1(+)CD8(+) T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer. Cancer Immunol Res. 2020 Jan;8(1):146-154. (IF 12.0, ESI)

6. Zhijie Wang, Jianchun Duan, Shangli Cai, Miao Han, Hua Dong, Jun Zhao, Bo Zhu, Shuhang Wang, Minglei Zhuo, Jiangguo Sun, Qiming Wang, Hua Bai, Jiefei Han, Yanhua Tian, Jing Lu, Tongfu Xu, Xiaochen Zhao, Guoqiang Wang, Xinkai Cao, Fugen Li, Dalei Wang, Yuejun Chen, Yuezong Bai, Jing Zhao, Zhengyi Zhao, Yuzi Zhang, Lei Xiong, Jie He, Shugeng Gao, Jie Wang* .Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. JAMA Oncol. 2019 May 1;5(5):696-702. (IF 31.7,C100,ESI)

7. Zhijie Wang, Ying Cheng, Tongtong An, Hongjun Gao, Kai Wang, Qing Zhou, Yanping Hu, Yong Song, Cuimin Ding, Feng Peng, Li Liang, Yi Hu, Cheng Huang, Caicun Zhou, Yuankai Shi, Li Zhang, Xin Ye, Meizhuo Zhang, Shaokun Chuai, Guanshan Zhu, Jin Hu,Yi-long Wu, Jie Wang*. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma(BENEFIT): a phase 2, single-arm multicentre clinicla trial. Lancet Respir Med. 2018 Sep;6(9):681-690.   (IF=23.0)

8. Xiaohui Ni, Minglei Zhuo, Zhe Su, Jianchun Duan, Yan Gao, Zhijie Wang, Chenghang Zong, Hua Bai,Alec R. Chapman, Jun Zhao, Liya Xu, Tongtong An, Qi Ma, Yuyan Wang, Meina Wu, Yu Sun, Shuhang Wang, Zhenxiang Li, Xiaodan Yang, Jun Yong, XiaoDong Su, Youyong Lu, Fan Bai, X. Sunney Xie, Jie Wang*. Reproducible Copy Number Variation Patterns among Single Circulating Tumor Cells of Lung Cancer Patients. Proc Natl Acad Sci USA. 2013 Dec 24; 110(52): 21083-8. (IF=11.2, ESI)

9. Hua Bai, Zhijie Wang, Keneng Chen, Jun Zhao, J. Jack Lee, Shuhang Wang, Qinghua Zhou, Minglei Zhuo, Li Mao, Tongtong An, Jianchun Duan, Lu Yang, Meina Wu, Zhen Liang, Yuyan Wang, Xiaozheng Kang, Jie Wang*. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol. 2012 Sep 1;30(25):3077-83. (IF=17.9, C100)

10. Hua Bai, Li Mao, Shuhang Wang, Jun Zhao, Lu Yang, Tongtong An, Xin Wang, Jianchun Duan Meina Wu, Qingzhi Guo, Xuyi Liu, Ninghong Liu, Yuye Wang, Jie Wang*. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol. 2009 Jun 1;27(16):2653-9. (IF=16.9C100)